	US 11,685,953 B2
	Biomarkers and methods of treating cancer
Alvaro Avivar Valderas, Cheshire (GB); Francisco Humberto Cruzalegui, Cheshire (GB); Kevin Hudson, Cheshire (GB); and Robert Kenneth McEwen, Cheshire (GB)
Assigned to ASTRAZENECA AB, Sodertalje (SE)
Appl. No. 15/760,858
Filed by ASTRAZENECA AB, Sodertaue (SE)
PCT Filed Sep. 16, 2016, PCT No. PCT/EP2016/072069 § 371(c)(1), (2) Date Mar. 16, 2018, PCT Pub. No. WO2017/046394, PCT Pub. Date Mar. 23, 2017.
Claims priority of provisional application 62/219,698, filed on Sep. 17, 2015.
Prior Publication US 2021/0130901 A1, May 6, 2021
Int. Cl. C12Q 1/68 (2018.01); C12Q 1/6886 (2018.01); C07D 401/12 (2006.01); A61P 35/00 (2006.01); A61P 35/02 (2006.01)

CPC C12Q 1/6886 (2013.01) [C07D 401/12 (2013.01); A61P 35/00 (2018.01); A61P 35/02 (2018.01); C12Q 2600/106 (2013.01); C12Q 2600/156 (2013.01)]

3 Claims

1. A method of treating a patient suffering from breast cancer, comprising:

(a) determining, in a sample which is representative of the cancer and was previously isolated from the patient, whether the patient's sample comprises

(i) a mutation selected from E17K, L52R, C77F, or Q79K in the patient's AKT1, AKT2, and/or AKT3 genes,

(ii) a wildtype or mutant MAP3K1 gene, and

(iii) a wildtype or mutant MAP2K4 gene;

(b) detecting in the patient's sample a mutation selected from E17K, L52R, C77F, or Q79K in the patient's AKT1, AKT2, and/or AKT3 genes; a wildtype MAP3K1 gene;

and a wildtype MAP2K4 gene; and

(c) administering to the patient an effective amount of 4-amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxy-propyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide.